SG11201503144VA - Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine d3 receptor - Google Patents
Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine d3 receptorInfo
- Publication number
- SG11201503144VA SG11201503144VA SG11201503144VA SG11201503144VA SG11201503144VA SG 11201503144V A SG11201503144V A SG 11201503144VA SG 11201503144V A SG11201503144V A SG 11201503144VA SG 11201503144V A SG11201503144V A SG 11201503144VA SG 11201503144V A SG11201503144V A SG 11201503144VA
- Authority
- SG
- Singapore
- Prior art keywords
- dopamine
- receptor
- respond
- modulation
- compounds suitable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261716824P | 2012-10-22 | 2012-10-22 | |
| US201361777114P | 2013-03-12 | 2013-03-12 | |
| PCT/EP2013/071947 WO2014064038A1 (en) | 2012-10-22 | 2013-10-21 | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine d3 receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201503144VA true SG11201503144VA (en) | 2015-06-29 |
Family
ID=49515329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201503144VA SG11201503144VA (en) | 2012-10-22 | 2013-10-21 | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine d3 receptor |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9376396B2 (en) |
| EP (1) | EP2909201B1 (en) |
| JP (1) | JP2016500683A (en) |
| KR (1) | KR20150074154A (en) |
| CN (1) | CN104854103B (en) |
| AR (1) | AR093099A1 (en) |
| AU (1) | AU2013336787B2 (en) |
| BR (1) | BR112015008992A2 (en) |
| CA (1) | CA2890247A1 (en) |
| IL (1) | IL238392A (en) |
| IN (1) | IN2015DN03837A (en) |
| MX (1) | MX2015005093A (en) |
| NZ (1) | NZ630281A (en) |
| RU (1) | RU2015119241A (en) |
| SG (1) | SG11201503144VA (en) |
| TW (1) | TWI607003B (en) |
| UY (1) | UY35090A (en) |
| WO (1) | WO2014064038A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9376396B2 (en) | 2012-10-22 | 2016-06-28 | AbbVie Deutschland GmbH & Co. KG | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor |
| UY35420A (en) | 2013-03-15 | 2014-10-31 | Abbvie Inc | ACILAMINOCICLOALQUILO COMPOUNDS APPROPRIATE TO TREAT DISORDERS THAT RESPOND TO THE MODULATION OF DOPAMINE D3 RECEIVER |
| AR095264A1 (en) | 2013-03-15 | 2015-09-30 | Abbvie Deutschland | ACILAMINOCICLOALQUILO COMPOUNDS APPROPRIATE TO TREAT DISORDERS THAT RESPOND TO THE MODULATION OF DOPAMINE D3 RECEIVER |
| WO2018021447A1 (en) | 2016-07-28 | 2018-02-01 | 塩野義製薬株式会社 | Nitrogen-containing condensed ring compound having dopamine d3 receptor antagonistic effect |
| CN111801330B (en) | 2018-01-26 | 2024-04-05 | 盐野义制药株式会社 | Fused ring compounds having dopamine D3 receptor antagonism |
| WO2019146740A1 (en) | 2018-01-26 | 2019-08-01 | 塩野義製薬株式会社 | Cyclic compound having dopamine d3 receptor antagonism |
| CN111770754B (en) * | 2019-01-30 | 2023-09-19 | 江苏豪森药业集团有限公司 | Polycyclic derivative regulator, preparation method and application thereof |
| WO2021083246A1 (en) * | 2019-10-29 | 2021-05-06 | 上海翰森生物医药科技有限公司 | Modifier of four-membered ring derivative, preparation method and application thereof |
| JP2024517752A (en) * | 2021-04-28 | 2024-04-23 | 上▲海▼翰森生物医▲薬▼科技有限公司 | Salts containing piperazine polycyclic derivatives, their crystalline forms, their preparation method and their use |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19728996A1 (en) | 1997-07-07 | 1999-01-14 | Basf Ag | Triazole compounds and their use |
| DE19735410A1 (en) | 1997-08-14 | 1999-02-18 | Basf Ag | New stable fumarate salt of pyrimidinol derivative dopamine D3 receptor ligand, having improved solubility and suitable for oral administration |
| DE10131543A1 (en) | 2001-06-29 | 2003-01-16 | Abbott Lab | Pyrimidinoxyalkylpiperazines and their therapeutic use |
| US20030166476A1 (en) | 2002-01-31 | 2003-09-04 | Winemiller Mark D. | Lubricating oil compositions with improved friction properties |
| DE10311065A1 (en) | 2003-03-13 | 2004-09-23 | Abbott Gmbh & Co. Kg | New 1-(cyclic amino-alkyl)-pyrimidin-2(1H)-one derivatives, are selective dopamine D3 receptor ligands useful for treating CNS disorders, especially schizophrenia or depression |
| TW200510395A (en) | 2003-06-05 | 2005-03-16 | Abbott Gmbh & Co Kg | Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor |
| DE102004027358A1 (en) | 2004-06-04 | 2005-12-29 | Abbott Gmbh & Co. Kg | Pyrimidine compounds and their use |
| DE102004027359A1 (en) | 2004-06-04 | 2005-12-29 | Abbott Gmbh & Co. Kg | Pyridin-2-one compounds and their use |
| US8202868B2 (en) | 2004-08-09 | 2012-06-19 | Abbott Gmbh & Co. Kg | 4-piperazinyl-pyrimidine compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor |
| DE102004061593A1 (en) | 2004-12-21 | 2006-06-22 | Abbott Gmbh & Co. Kg | Substituted N-heterocyclic compounds and their therapeutic use |
| HUP0500170A3 (en) | 2005-02-03 | 2007-11-28 | Richter Gedeon Nyrt | Piperazine derivatives, process for producing them and pharmaceutical compositions containing them |
| EP1870405A1 (en) | 2006-06-22 | 2007-12-26 | Bioprojet | Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands |
| WO2008065500A2 (en) | 2006-11-30 | 2008-06-05 | Pfizer Products Inc. | Heteroaryl amides as type i glycine transport inhibitors |
| HUP0700269A2 (en) * | 2007-04-11 | 2009-04-28 | Richter Gedeon Nyrt | Pyrimidinyl-piperazines useful as d3/d2 receptor ligands, pharmaceutical compositions containing them and their use |
| AU2008270445A1 (en) | 2007-07-02 | 2009-01-08 | F. Hoffmann-La Roche Ag | 2 -imidazolines having a good affinity to the trace amine associated receptors (TAARs) |
| PA8802101A1 (en) | 2007-11-02 | 2009-08-26 | Abbott Gmbh & Co Kg | SUITABLE 1,2,4-3,5-DIONA COMPOUNDS FOR THE TREATMENT OF DISORDERS THAT RESPOND TO THE MODULATION OF DOPAMINE D3 RECEIVER |
| US7875610B2 (en) | 2007-12-03 | 2011-01-25 | Richter Gedeon Nyrt. | Pyrimidinyl-piperazines useful as D3/D2 receptor ligands |
| CA2730002A1 (en) | 2008-09-23 | 2010-04-01 | F. Hoffmann-La Roche Ag | Pyridinylpiperazin derivatives useful as modulators of dopamine d3 receptors |
| US8586579B2 (en) | 2010-06-21 | 2013-11-19 | Hoffmann-La Roche Inc. | Anellated pyridine compounds |
| US8470828B2 (en) | 2010-07-06 | 2013-06-25 | Hoffmann-La Roche Inc. | Anellated pyridine compounds |
| US9376396B2 (en) | 2012-10-22 | 2016-06-28 | AbbVie Deutschland GmbH & Co. KG | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor |
| UY35420A (en) | 2013-03-15 | 2014-10-31 | Abbvie Inc | ACILAMINOCICLOALQUILO COMPOUNDS APPROPRIATE TO TREAT DISORDERS THAT RESPOND TO THE MODULATION OF DOPAMINE D3 RECEIVER |
-
2013
- 2013-10-11 US US14/051,626 patent/US9376396B2/en active Active
- 2013-10-21 WO PCT/EP2013/071947 patent/WO2014064038A1/en active Application Filing
- 2013-10-21 CA CA2890247A patent/CA2890247A1/en not_active Abandoned
- 2013-10-21 BR BR112015008992A patent/BR112015008992A2/en not_active IP Right Cessation
- 2013-10-21 CN CN201380067566.XA patent/CN104854103B/en not_active Expired - Fee Related
- 2013-10-21 MX MX2015005093A patent/MX2015005093A/en unknown
- 2013-10-21 UY UY0001035090A patent/UY35090A/en not_active Application Discontinuation
- 2013-10-21 RU RU2015119241A patent/RU2015119241A/en not_active Application Discontinuation
- 2013-10-21 JP JP2015537290A patent/JP2016500683A/en active Pending
- 2013-10-21 EP EP13785389.1A patent/EP2909201B1/en active Active
- 2013-10-21 AU AU2013336787A patent/AU2013336787B2/en not_active Ceased
- 2013-10-21 KR KR1020157013554A patent/KR20150074154A/en not_active Application Discontinuation
- 2013-10-21 NZ NZ630281A patent/NZ630281A/en not_active IP Right Cessation
- 2013-10-21 SG SG11201503144VA patent/SG11201503144VA/en unknown
- 2013-10-22 TW TW102138129A patent/TWI607003B/en not_active IP Right Cessation
- 2013-10-22 AR ARP130103832A patent/AR093099A1/en unknown
-
2015
- 2015-04-20 IL IL238392A patent/IL238392A/en not_active IP Right Cessation
- 2015-05-06 IN IN3837DEN2015 patent/IN2015DN03837A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ630281A (en) | 2016-08-26 |
| TW201427957A (en) | 2014-07-16 |
| KR20150074154A (en) | 2015-07-01 |
| RU2015119241A (en) | 2016-12-20 |
| EP2909201B1 (en) | 2017-02-22 |
| TWI607003B (en) | 2017-12-01 |
| CA2890247A1 (en) | 2014-05-01 |
| IL238392A0 (en) | 2015-06-30 |
| MX2015005093A (en) | 2015-09-25 |
| UY35090A (en) | 2014-05-30 |
| EP2909201A1 (en) | 2015-08-26 |
| IL238392A (en) | 2017-09-28 |
| IN2015DN03837A (en) | 2015-10-02 |
| AR093099A1 (en) | 2015-05-20 |
| US9376396B2 (en) | 2016-06-28 |
| BR112015008992A2 (en) | 2017-07-04 |
| CN104854103A (en) | 2015-08-19 |
| CN104854103B (en) | 2018-01-02 |
| AU2013336787B2 (en) | 2017-06-22 |
| JP2016500683A (en) | 2016-01-14 |
| AU2013336787A1 (en) | 2015-05-14 |
| WO2014064038A1 (en) | 2014-05-01 |
| US20140194437A1 (en) | 2014-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1258404A1 (en) | Modulation of androgen receptor expression | |
| HK1215375A1 (en) | Use of akkermansia for treating metabolic disorders | |
| IL238392A (en) | Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine d3 receptor | |
| ZA201500076B (en) | Crystalline forms of androgen receptor modulator | |
| HK1207073A1 (en) | Agents for treating disorders involving modulation of ryanodine receptors | |
| HK1210962A1 (en) | Methods for treatment of atherosclerosis | |
| PL2919796T3 (en) | Use of akkermansia for treating metabolic disorders | |
| IL234627B (en) | Amorphous solid dispersion for treatment of brain cancer | |
| HK1207566A1 (en) | Compositions for improvement of brain function | |
| IL235317A0 (en) | Composition for treating metabolic disorders | |
| PL3524260T3 (en) | Pharmaceutical compositions for treatment of inappetence | |
| GB201010359D0 (en) | Compounds for treating proliferative disorders | |
| PL2882724T3 (en) | Compounds for use in the treatment of disorders that are ameliorated by inhibition of hdac | |
| ZA201501038B (en) | Treatment of wax | |
| GB201207363D0 (en) | Compounds for the treatment of metabolic disorders | |
| GB201207359D0 (en) | Compounds for the treatment of metabolic disorders | |
| GB201212717D0 (en) | Treatment of musculoskeletal conditions | |
| GB201009495D0 (en) | Compounds for treating proliferative disorders |